The PRADA II trial showed that while sacubitril/valsartan did not significantly prevent LVEF decline compared to placebo, it improved global longitudinal strain and attenuated increases in NT-proBNP and troponin, suggesting a protective effect on subclinical myocardial injury during adjuvant breast cancer therapy [141]. This evidence concerns the gene NPPB and breast carcinoma.